Compare Boston Scientific Corporation (BSX) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs PepsiCo, Inc. — how do they compare? Boston Scientific Corporation trades at $43.5 (market cap $66.37B), while PepsiCo, Inc. trades at $136.82 (market cap $184.87B). The key difference: PepsiCo, Inc. is far larger — about 2.8× Boston Scientific Corporation's market cap, and PepsiCo, Inc. pays a 4.37% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | PEP | |
|---|---|---|
Market Cap | $66.37B | $184.87B |
Sector | Health | Consumer Staples |
52-Week High | $108.14 | $170.44 |
52-Week Low | $42.63 | $133.81 |
Enterprise Value | $75.94B | $227.37B |
Dividend Yield | — | 4.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
PepsiCo (PEP) trades at $136.03, down 1.78% for the day, with a bearish technical signal and mixed sentiment. The stock shows strong profitability with a 10.78% net margin and 51.59% ROE, though revenue growth remains modest. Recent news highlights price adjustments for snacks after consumer pushback on high costs, while analyst consensus leans Hold with a $159.27 price target.
The outlook is cautious near-term due to technical weakness and pricing challenges, but fundamentals support long-term stability. Risks include competitive pressures and margin compression, while opportunities lie in operational improvements and dividend reliability. Investors should weigh current volatility against the company's solid cash flow and market position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
